Moderna, the biotechnology company best known for its COVID-19 vaccine, has raised its revenue outlook for 2026, signaling that its pandemic-era business still has momentum—especially outside the United States. The company now expects revenue growth of 15% to 25% in 2026, up from its earlier forecast of up to 10%. It also aims to generate about half of that year's sales from international markets.
The updated guidance reflects a broader shift in how Moderna sees its future. While the company's name is still closely tied to its COVID-19 shot, it is working to build a wider portfolio of mRNA-based products, including a flu vaccine and experimental cancer treatments. But for the near term, the numbers still depend heavily on how well it can sell its existing vaccines around the world.
Why international sales matter
For years, Moderna's revenue was heavily concentrated in the United States, where its COVID-19 vaccine was a major driver. Now, the company is betting that overseas markets—Europe, Asia, and other regions—will become a much bigger part of the story. That shift is not just about geography; it changes the financial dynamics of the business.
When a company earns a large share of its revenue in foreign currencies, its reported results in U.S. dollars become more sensitive to exchange rates. If the dollar strengthens, sales earned in euros, yen, or other currencies translate into fewer dollars, which can make growth look weaker even if local demand is steady. Conversely, a weaker dollar can flatter the numbers. This is known as currency translation, and it can add noise to quarterly earnings reports.
Moderna can use hedging—financial contracts that lock in exchange rates—to reduce some of this volatility. But hedging is not free, and it rarely eliminates the impact entirely. As a result, investors may find it harder to interpret Moderna's quarterly results as a clean signal of vaccine demand.
This is a common challenge for multinational companies. For example, Engie's outlook brightened recently as analysts lifted profit forecasts, partly reflecting currency and energy market dynamics. Similarly, SG Holdings raised its profit outlook after a strong first half, showing how company-specific factors can drive guidance changes.
What it means for investors
For everyday investors, Moderna's updated guidance is a reminder that growth forecasts are not just about how many doses a company sells. They also depend on where those sales happen and how currencies move. A company that generates half its revenue overseas will see its results swing with the dollar, which can make "beats" and "misses" harder to read.
That doesn't mean the underlying business is weak. Moderna's decision to raise its outlook suggests management sees real demand for its vaccines beyond the U.S. border. But it does mean that investors should pay attention to currency trends when evaluating the company's performance.
Moderna is also trying to diversify beyond COVID-19. Its mRNA platform has potential in other areas, including respiratory viruses and oncology. But those programs are still in development, and the near-term financials will likely hinge on how well the company commercializes its existing products globally.
For context, other companies have faced similar currency headwinds. Rightmove trimmed its 2026 outlook after a Bank of England rate hike cooled the housing market, showing how macroeconomic factors can affect guidance. And JFE cut its profit outlook after a storm hit its steelworks, illustrating that unexpected events can also force revisions.
Moderna's raised outlook is a positive sign, but it comes with a caveat: the more global the company becomes, the more its reported numbers will reflect currency movements. Investors should keep an eye on both vaccine demand and the dollar's direction in the coming quarters.
As always, this is not a recommendation to buy or sell Moderna stock. It's simply a look at what the company's latest guidance means and why it matters for your portfolio.
